Aptevo Therapeutics's gross profit for the
three
months ended in Dec. 2024 was $0.00 Mil. Aptevo Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.
Aptevo Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
During the past 12 years, the highestGross Margin % of Aptevo Therapeutics was 65.82%. The lowest was -24.86%. And the median was 50.50%.
Aptevo Therapeutics Gross Profit Historical Data
The historical data trend for Aptevo Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aptevo Therapeutics's Gross Profit
For the Biotechnology subindustry, Aptevo Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's Gross Profit falls into.
Aptevo Therapeutics Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Aptevo Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aptevo Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Aptevo Therapeutics Gross Profit Related Terms
Thank you for viewing the detailed overview of Aptevo Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APVO has been successfully added to your 